CO SB 24-203

Title: Prescription Drug Board Consider Rare Disease Advisory Council
Author: Chris deGruy Kennedy

Summary
Current law requires the Colorado prescription drug affordability review board (board) to take certain measures in determining whether to conduct an affordability review for an identified prescription drug. The bill requires the board, in making such a determination, to consider whether the drug has an approved orphan drug designation for one or more rare diseases and no other indications and, if so, to consider input from consumers and the Colorado rare disease advisory council (council). Current law requires the board, in performing an affordability review, to consider certain information. The bill requires the board to consider input from the council. (Note: This summary applies to the reengrossed version of this bill as introduced in the second house.)

Status
House Committee on Health & Human Services Refer Unamended to House Committee of the Whole

Bill Documents
CO SB 24-203 - Introduced Version
2024-04-08 - CO SB 24-203 (Introduced Version)